What would be your treatment approach in a premenopausal BRCA2+ patient with cT2N0 grade 2-3, ER negative, PR variably positive (30%; staining weak to high), HER2 negative breast cancer?

Would you still treat with neoadjuvant KEYNOTE-522?

Answer from: Medical Oncologist at Academic Institution

Since weakly hormone-positive, HER2-negative breast cancer behaves more similarly to triple-negative breast cancer than strongly hormone receptor-positive breast cancer (Poterala et al., PMID 35676188), I would approach this patient similarly to patients with stage 2 triple-negative breast cancer. I...

Comments

Medical Oncologist at NYU Winthrop Hospital
The patient is not triple negative. She is PR-posi...

Answer from: Medical Oncologist at Academic Institution

Yes, I would treat as TNBC with KN522 and if not a pCR, give adjuvant olaparib with pembro.

Comments

Medical Oncologist at NYU Winthrop Hospital
There is no data to combine pembrolizumab with ola...

Medical Oncologist at H Lee Moffitt Cancer Center, University of South Florida
There is safety and efficacy data from the KEYLYNK...

Medical Oncologist
This patient is 30% PR positive (staining weak to ...

Medical Oncologist at H Lee Moffitt Cancer Center, University of South Florida
Hello @Mayer. Since PR expression is driven by ER ...

Medical Oncologist
Thank you for the detailed response. This explanat...

Medical Oncologist at Chitra Venkatraman, M.D., P.A.
Thank you so much for explaining well.

Answer from: Medical Oncologist at Community Practice

I agree - would treat at TNBC with KN-522

Please select the option that best describes you:

What would be your treatment approach in a premenopausal BRCA2+ patient with cT2N0 grade 2-3, ER negative, PR variably positive (30%; staining weak to high), HER2 negative breast cancer?

Related Questions